Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

Horizon Therapeutics plc (NASDAQ:HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. 
  • NMOSD is a neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain, and brain stem.
  • During the 28-week, 89% of 161 patients in the Uplinza treatment group remained attack-free compared to 58% of 52 patients in the placebo group.
  • Of the 18 total attacks in the Uplinza group, 12 (67%) were minor, and six (33%) were major, compared to 12 (55%) minor attacks and 10 (45%) major attacks among the 22 attacks in the placebo group.
  • A new post hoc analysis of this data was conducted to understand the effect of Uplinza on the severity of attacks in the 11% of people in the clinical trial who were not attack-free after being treated with Uplinza. 
  • The analysis also evaluated the relationship between these attacks' severity and disease activity biomarkers, such as serum glial fibrillary acidic protein (sGFAP) and serum neurofilament (sNfL).
  • Price Action: HZNP shares are down 0.93% at $97.26 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.